IMMUNOCHEMICAL EVALUATION OF SPINAL CORD INJURY BIOMARKER S100B IN EXPERIMENTAL ANIMAL MODEL

Аннотация

The implementation of biomarkers in spinal cord injury (SCI) provides a useful tool to support clinical decision-making in the acute phase. S100b has been considered specific to the nervous system. In cases of SCI, this protein is released from nerve cells, and its concentration increases in the cerebrospinal fluid and blood under various CNS conditions. Over the past 20 years, several experimental and in vivo studies have been conducted on the prognostic role of S100b in tissues, serum or cerebrospinal fluid after SCI, which concluded that this biomarker could be a real-time indicator of early stages of spinal cord injury. S100b levels in serum and cerebrospinal fluid in experimental studies increased rapidly for a short time and then gradually decreased and reached normal levels a few days after injury. In addition, S100b has been studied as a predictor of initial spinal cord injury, which directly reflects the severity of SCI. Significant changes in serum S100b levels were also observed in patients with vertebral fractures and spinal cord injury. S100b protein may be a useful tool after spinal cord injury for early detection of the extent of spinal cord injury and the degree of neurological outcome within 14 days after injury.